Search the Newsreel

Cognition Therapeutics, Inc. (CGTX) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Cognition Therapeutics, Inc. (CGTX), including its current stock price, historical data, company overview, financial performance, and analyst ratings. CGTX is a clinical-stage biopharmaceutical company developing therapeutics for age-related degenerative diseases, with its lead candidate zervimesine in …

Organon & Co. (OGN) Stock Forecasts

This article provides a brief overview of Organon & Co. (OGN), a pharmaceutical company focused on women's health, biosimilars, and established brands. It references an Argus research report from August 5, 2026, which includes a summary of the company and its current stock price …

Sera Prognostics Q1 2026 Earnings: In-Line Loss of -$0.17 Per Share as Shares Advance 3.5% - EBITDA Analysis

Cognizant Technology Solutions Corp (CTSH) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with …

Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly reduced its stake in Organon & Co. ($OGN) by 3.5% in the first quarter, selling over 118,000 shares while still retaining a substantial holding. Despite this reduction and a consensus "Reduce" rating from analysts with an average price target …

Cognyte Software Ltd (CGNT) Stock News Today

This article provides an overview of Cognyte Software Ltd (CGNT) stock news on TradingKey. It displays current stock performance, market capitalization, and indicates that more news, earnings reports, and analyst ratings are expected soon. The page serves as a hub for financial information regarding …

Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary

Cognition Therapeutics Inc. reported a consolidated net loss of $3.9 million for Q2 2026, an improvement from a $6.7 million loss in Q2 2025, with diluted loss per share at $(0.04). The company had no product revenue and relied on grant funding, which totaled …

Cognizant (CTSH) Q2 2026 Earnings Call Transcript

Organon & Co stock hits 52-week high at 13.61 USD

Organon & Co (OGN) stock has reached a new 52-week high of $13.61, marking a 47.51% increase over the past year and reflecting strong investor confidence. The company also announced several recent developments, including a global licensing agreement for Miudella, exclusive commercialization rights for …

Sera Prognostics Inc (SERA) Stock News Today

Sera Prognostics Inc (SERA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cognex Q2 Earnings Call Centers on AI and Data Center Growth

Cognex's Q2 2026 earnings call highlighted growth driven by an improving industrial cycle and a strategic focus on AI-enabled machine vision, new customers, and emerging markets like the data center supply chain. The company emphasized its AI platforms, customer expansion, and efforts to maintain …

Organon & Co (OGN) Stock News Today

Sera Prognostics (SERA) Q1 2026 Earnings: EPS Matches Estimates at -$0.17, Stock Flat - Guidance Upgrade Report

Sera Prognostics (SERA) Q1 2026 Earnings: EPS Matches Estimates at -$0.17, Stock Flat - Earnings Revision Downgrade

Cognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027

(RTTNews) - Cognition Therapeutics, Inc. (CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, reported second quarter results reflecting a narrowed net loss and provided a business update. The company's lead candidate, Zervimesine (CT1812), is an investigational once-daily oral therapy being evaluated …

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Cognition Therapeutics reported its financial results for the second quarter of 2026, highlighting progress in its clinical and corporate priorities, particularly for its lead candidate zervimesine. The company held discussions with the FDA for a Phase 3 trial in dementia with Lewy bodies (DLB) …

Cognex (CGNX) Stock Drops Despite Record Margins And Raised Outlook

Cognex Corp (CGNX) (Q2 2026) Earnings Call Highlights: Record Revenue and Margin Expansion Fuel ...

Cognex Corp (CGNX) reported record quarterly revenue in Q2 2026, up 17% year-over-year, alongside significant margin expansion, with adjusted EBITDA margin increasing 1,150 basis points to 32.2%. The company saw strong demand in logistics, electronics, and semiconductor markets, driven by the growing data center …

Cognition plans mid-2027 dementia trial; patent could extend to 2045

Cognition Therapeutics (NASDAQ: CGTX) reported a Q2 2026 net loss of $3.9 million, a significant reduction from $6.7 million in Q2 2025. The company announced its intention to initiate a Phase 3 trial for zervimesine in dementia with Lewy bodies (DLB) psychosis in mid-2027 …

OGN (NYSE: OGN) details 14,761-share Rule 144 common stock sale plan

Organon & Co. (OGN) has filed a Rule 144 notice for the proposed sale of 14,761 shares of common stock through Morgan Stanley Smith Barney LLC, valued at $200,306.77. The filing also details future restricted stock vesting events, including 2,384 shares on November 7, …

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics (CGTX) reported a Q2 loss of $0.04 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss, marking a 33.33% surprise. However, the company missed revenue estimates, posting -$1 million against an expectation of zero revenue, and its shares have dropped …

Earnings call transcript: Cognex posts record Q2 2026 revenue, shares slip

Cognex Corp. reported record second-quarter 2026 revenue of $291 million, up 17% year-over-year, and adjusted earnings per share of $0.45, surpassing analyst estimates. Despite strong financial performance and an optimistic full-year outlook, the company's stock experienced a slight slip in after-hours trading, likely due …

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Alpha Cognition Inc. (ACOG) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results …

COGNEX CORP 2026: Revenue $291.26M, EPS $0.43— 10-Q Summary

COGNEX CORP (CGNX) reported strong financial results for the quarter ended 2026, with revenue reaching $291.26 million and diluted EPS of $0.43, significantly up from the prior year. The growth was driven by broad-based demand, favorable foreign exchange, and strong geographic performance in Greater …

Cognyte Secures ~$5 Million Expansion with Long-Standing EMEA National Security Customer

Cognyte Software Ltd. announced a new three-year subscription agreement valued at approximately $5 million with an existing EMEA national security customer. This expansion will allow the agency to scale its investigative operations with AI-powered analytics to address growing data volumes and increasingly sophisticated threats. …

Alpha Cognition (ACOG) to Announce Quarterly Earnings on Thursday

Alpha Cognition (NASDAQ:ACOG) is scheduled to release its Q2 2026 earnings on Thursday, August 13th, after market close. Analysts anticipate a loss of $0.39 per share on $4.38 million in revenue. The company previously reported a smaller loss than expected and exceeded revenue estimates …

What Does Cognizant Technology Solutions (CTSH) Global AI Push Mean For Investors?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cognizant Technology Solutions (NasdaqGS:CTSH) launched a dedicated EMEA AI Unit to support enterprise AI deployment across the region. The company entered a partnership with …

Why Cognex (CGNX) Is Up 7.6% After Record Q2 Beat, Higher Guidance and Dividend Hike

Cognex Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CGNX) 2026-08-06

Cognex (NASDAQ: CGNX) lifts Q2 2026 profit on 17% revenue growth

Cognition Therapeutics (CGTX) Earnings Date and Reports 2026

Cognex earnings beat by $0.03, revenue fell short of estimates

Cognex (NASDAQ: CGNX) reported strong Q2 earnings, beating analyst EPS estimates by $0.03 with an EPS of $0.45, although revenue of $291M fell slightly short of the consensus estimate of $291.76M. The company's stock has performed well, rising 7.69% in the last 3 months …

Cognizant Technology Solutions (CTSH) jumps 21.8% in weekly rebound

The IT services stock’s four-week advance and heavier activity put the move back on active-mover screens, while momentum readings remain uneven.

Is Cognex Corp (CGNX) Overvalued After Q2 Earnings Beat? EPS Hits $0.43, GF Score: 83/100